Medivis

Medivis is a provider of an AI-powered and AR-guided surgical intelligence platform. The company offers FDA-cleared surgical navigation solutions including Spine Navigation for open and minimally invasive spine surgery, Cranial Navigation for EVDs, subdural evacuations, and craniotomies, and Prostate Navigation for prostate biopsies and tumor ablations under research. The SurgicalAR platform is the leading enterprise solution for 3D surgical visualization, transforming complex 2D cross-sectional imaging from CTs and MRIs into high-fidelity 3D visualizations. SurgicalAR is FDA-cleared, CE-marked, and KFDA-cleared, featuring on-premise IT with certified gold-standard security, livestream imaging to virtual monitors, model segmentation and STL/OBJ import, photorealistic renderings, an integrated Medivis AI Agent called Maia, infrared instrument tracking, and spatial interactions with hands and voice. Hardware configurations include Medivis PRO for operating rooms with 27-inch touch monitor, 4K graphics, and NVIDIA GPU; Medivis CORE for ICUs and clinics with 17-inch touch monitor; and Medivis VIEWER for office-based surgical planning. The platform has been used in over 2,000 surgeries across 40-plus hospitals and medical schools with 46 patents granted and pending. Named TIME Best Inventions of 2023 and Fast Company Most Innovative Company 2024. Founded in 2016 and headquartered in New York, United States, Medivis has raised approximately 22.3 million at the Series A stage with investors including Initialized Capital, Thrive Capital, Mayo Clinic, 35V, Coalition Operators, Alumni Ventures, MTS StartUp Hub, and Vectr Ventures.